A comparison of an anti-CD25 immunotoxin, Ontak and anti-CD25 microbeads for their ability to deplete alloreactive T cells in vitro

Bone Marrow Transplantation

Volumn 37, Issue 6, 2006, Pages 559-567

  Vaclavkova, P ^a   Cao, Y ^a   Wu, L K ^a   Michalek, J ^a   Vitetta, Ellen S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Alloreactive T cells; Anti CD25 immunotoxin; Graft versus host disease; Magnetic cell sorting; Ontak; Selective depletion

Indexed keywords

DENILEUKIN DIFTITOX; IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR ALPHA;

ALLOIMMUNITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL ACTIVITY; CONTROLLED STUDY; EX VIVO STUDY; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; IN VITRO STUDY; INCIDENCE; MIXED LYMPHOCYTE REACTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T CELL DEPLETION;

ANTIGENS, CD; ANTIGENS, CD8; CD4-POSITIVE T-LYMPHOCYTES; DIPHTHERIA TOXIN; HUMANS; IMMUNOTOXINS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOCYTE DEPLETION; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; REFERENCE VALUES; T-LYMPHOCYTES;

EID: 33644891348     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705286     Document Type: Article

References (35)

1. Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667-674.
2. Murphy WJ, Blazar B. New strategies for preventing graft-versus-host disease. Curr Opin Immunol 1999; 11: 509-515.
3. Przepiorka D, Ippoliti C, Koberda J, Chan KW, Khouri IF, Fisher HE et al. Interleukin-2 for prevention of graft-versus-host disease after haploidentical marrow transplantation. Transplantation 1994; 58: 858-860.
4. Ferrara JL, Cooke KR, Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol 2003; 78: 181-187.
5. Ho VT, Soiffer RJ. The history and future of T cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001; 98: 3192-3204.
6. O'Reilly RJ, Collins N, Dinsmore R, Kernan N, Siena S, Brochstein J et al. Transplantation of HLA-mismatched marrow depleted of T cells by lectin agglutination and E-rosette depletion. Tokai J Exp Clin Med 1985; 10: 99-107.
7. Michalek J, Collins RH, Vitetta ES. Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin. Neoplasia 2003; 50: 296-299.
8. Solomon SR, Tran T, Carter CS, Donelly S, Hensel N, Schindler J et al. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: A strategy for GVHD prophylaxis in allogeneic peripheral blood stem cell transplantation. Cytotherapy 2002; 4: 395-406.
9. Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R et al. Selective depletion of alloreactive donor lymphocytes - a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005; 106: 1123-1129.
10. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, Vitetta E, Schindler J, Chedeville G et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: A phase 1/2 study. Lancet 2002; 360: 130-137.
11. Amrolia P, Mucioli-Casadei G, Yvon E, Huls H, Sili U, Wieder D et al. Selective depletion of alloreactive T cells without loss of anti-viral or anti-leukemic responses. Blood 2004; 104: 1605 (Erratum).
12. Amrolia PJ, Mucioli-Casadei G, Huls H, Gotsolva T, Durett A, Weiss H et al. Adaptive immunotherapy with allodepleted donor T cells improves immune reconstruction after haplo-identical stem cell transplant. 2005, submitted.
13. Eklund JW, Kuzel TM. Denileukin diftitox: A concise clinical review. Expert Rev Anticancer Ther 2005; 5: 33-38.
14. Jansen J, Hanks S, Akard LP, Thompson JM, Burns S, Chang Q et al. Immunomagnetic CD4+ and CD8+ cell depletion for patients at high risk for severe acute GVHD. Bone Marrow Transplant 1996; 17: 377-382.
15. Herrera CS, Torres AJ Garcia-Castellano JM, Roman J, Martin C, Serrano J et al. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft. Bone Marrow Transplant 1999; 5: 443-450.
16. Garderet L, Snell V, Przepiorka D, Schenk T, Lu JG, Marini F et al. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation 1999; 61: 124-130.
17. Fehse B, Goldmann M, Frerk O, Bulduk M, Zander AR. Depletion of alloreactive donor T cells using immunomagnetic cell selection. Bone Marrow Transplant Suppl 2000; 2: S39-S42.
18. Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related Interleukin-2 fusion protein. Protein Eng 1987; 1: 493-498.
19. Re GG, Waters C, Poisson L, Willingham MC, Sugamura K, Frankel AE. Interleukin 2 (IL-2) receptor expression and sensitivity to diptheria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res 1996; 56: 2590-2595.
20. Ghetie V, Thorpe P, Ghetie MA, Knowles P, Uhr JW, Vitetta ES. The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond. J Immunol Methods 1991; 142: 223-230.
21. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4+ CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193: 1285-1294.
22. Bousvaros A, Stevens AC, Strom TB, Murphy J, Lamont JT. Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes. Dig Dis Sci 1997; 42: 1542-1548.
23. Shao RH, Tian X, Gorgun G, Urbano AG, Foss FM. Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene. Leuk Res 2002; 26: 1077-1083.
24. + T cells by virtue of their receptor β loci sequences. Proc Natl Acad Sci USA 2003; 100: 1180-1184.
25. Barrett AJ, Malkovaska V. Graft-versus-leukaemia: Understanding and using the alloimmune response to treat haematological malignancies. Br J Haematol 1996; 93: 754-761.
26. Zeiser R, Marks R, Bertz H, Finke J. Immunopathogenesis of acute graft-versus-host disease: Implications for novel preventive and therapeutic strategies. Ann Hematol 2004; 83: 551-565.
27. Barrett AJ, Mavroudis D, Tisdale J, Molldrem J, Clave E, Dunbar C et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 1998; 21: 543-551.
28. Cavazzana-Calvo M. Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation 1990; 50: 1-7.
29. Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 1224-1226.
30. Shaughnessy PJ, Bachier C, Grimley M, Freytes CO, Callander NS, Essell JH et al. Denileukin diftitox for treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11: 188-193.
31. Oluwole SF, Oluwole OO, DePaz HA, Adeyeri AO, Witkowski P, Hardy MA. CD4+CD25+ regulatory T cells mediate acquired transplant tolerance. Transpl Immunol 2003; 11: 287-293.
32. BaecherAllen C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 1245-1253.
33. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531-562.
34. Koenen HJ, Fasse E, Joosten I. CD27/CFSE-based ex vivo selection of highly suppressive alloantigen-specific human regulatory T cells. J Immunol 2005; 174: 7573-7583.
35. Mielke S, Rezvani K, Soloman SR, Kilical Y, Savani BN, Wisch L et al. Reconstitution of regulatory T cells after selective depletion of CD25+ host-reactive donor lymphocytes from allografts and association with acute graft-versus-host-disease (ASH abstract), 2005, in press.